Darunavir with FUZEON provides HIV patients a better chance to reach undetectable viral load
... However guidelines issued by major health associations such as the US Department of Health and Human Services (DHHS), the International AID...World's first approval of new HIV drug TMC114 provides potent new treatment option with FUZEON
Basel (CH), 23 June 2006. The US approval of TMC114 (darunavir), a new boosted protease inhibitor (PI), provides the opportunity to build a potent new treatment combination with the fusion inhibitor FUZEON (enfuvirtide) that can successfully combat the HIV virus in treatment resistant patients.... ...Data have shown that up to two-thirds of patients with extensive prior exposure to anti-HIV drugs...Investigational boosted protease inhibitor, TMC114, works better with FUZEON
Exciting interim data presented at the annual ICAAC* conference show that adding FUZEON (enfuvirtide) to the investigational boosted protease inhibitor (PI), TMC114/r, more than doubles the proportion of patients reaching undetectable levels of the virus.... ...This latest study provides further evidence that FUZEON now makes undetectable viral loads more achievable for patients failing on their...TPV EU approval provides new HIV active drug to be combined with FUZEON
The clinical trials RESIST I and II showed that almost double the proportion of patients who received FUZEON plus tipranavir/r showed a 90 percent drop in viral load compared with patients not receiving FUZEON. This FUZEON effect was shown in other clinical trials combining FUZEON with other boosted protease inhibitors, including lopinavir/r and TMC 114/r....... The use of FUZEON with tipranavir...New HIV guidelines support use of FUZEON + active boosted PI for treatment-experienced patients
Basel (CH), 14 October 2005. The importance of the drug FUZEON (enfuvirtide) in the management of HIV has been officially recognised by the US Department of Health and Human Services (DHHS). Their newly updated HIV/AIDS treatment guidelines support the use of FUZEON with an active boosted protease inhibitor (PI) for the management of treatment-experienced patients. ......"These guidelines clea...Data presented at IAS build a compelling case for FUZEON (enfuvirtide, formerly known as T-20) to be combined with the newest drugs to give patients facing resistance their best chance of achieving undetectable viral load the optimal treatment goal for all people living with HIV. ...... "Undetectable viral load should be the ultimate treatment goal for all triple-class experienced patients. FUZ...